Biotech News

Xeris Announces Updates to Its Board of Directors

Xeris Pharmaceuticals (XERS)Xeris Pharmaceuticals2026-06-30 11:00 ESTCompany update

Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 CHICAGO --(BUSINESS WIRE)--Jun. 30, 2026-- Xeris Biopharma Holdings, Inc.

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Stock data

Close: 7.36 USD
Market cap: 1.04B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Xeris Announces Updates to Its Board of Directors

Related news

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Vistagen Appoints Douglas J. Williamson to its Board of Directors

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Xeris Pharmaceuticals

Recent company news

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Announces Updates to Its Board of Directors

Stock data